Plain-English translation of NCT06929507 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether Faricimab, a new eye injection medication, affects kidney function differently than an existing similar medication called Aflibercept. Both drugs are used to treat vision problems caused by diabetes or age-related macular degeneration. Researchers want to understand if this new treatment is safe for your kidneys while it helps your eyes.
Diabetic patients often have both eye and kidney problems related to their diabetes. While eye injection medications work well for vision, doctors need to know whether this medication might affect kidney function, which is crucial for overall health.
You likely qualify if…
You likely don't qualify if…
You will receive eye injections of one of the two medications and have regular check-ups at baseline and at 6 and 12 months. At each visit, you'll have blood and urine tests to monitor your kidney function, eye pressure checks, and imaging scans of your retina. The study lasts one year in total.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Greece
Sponsor
University Hospital, Alexandroupolis
Enrollment target
~60 participants
Started
March 2025
Primary completion
March 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Last updated on clinicaltrials.gov in April 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Asli Perente, Dr
University Hospital, Alexandroupolis
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.